Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | USP21 | Q9UK80 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609219 | 1.00 | RAB9A (0.60) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL28731673 | 0.88 | CCR3 (0.51) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL28731672 | 0.88 | CCR3 (0.51) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL4362723 | 0.86 | ALDH1A1 (0.59) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL3927028 | 0.86 | CTSL (0.71) | RAB9ATP53CTSLGAAALDH1A1 | |
| SCHEMBL28790851 | 0.86 | CTSL (0.71) | RAB9ATP53CTSLGAAALDH1A1 | |
| SCHEMBL28604598 | 0.86 | RAB9A (0.70) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL4368609 | 0.85 | RAB9A (0.60) | RAB9ANPC1TP53SMN1; SMN2CA2 | |
| SCHEMBL27761117 | 0.85 | CTSL (0.62) | RAB9ATP53CTSLGAAALDH1A1 | |
| SCHEMBL8133358 | 0.84 | MEN1 (0.51) | RAB9ANPC1TP53SMN1; SMN2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026848-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | claimed |
| WO-2023023269-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | claimed |
| JP-2002512960-A | — | — | 2002-05-08 | — | — | JP | claimed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | claimed |
| CN-121891531-A | Use of CCR3 antagonists as medicaments for the treatment of stress dermatitis | 复旦大学 | 2026-04-21 | — | — | CN | disclosed |
| US-20250026848-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-01-23 | — | — | US | disclosed |
| US-20250019772-A1 | Method and System of Augmenting Cancer Therapy | UNIV MIAMI (US) | 2025-01-16 | — | — | US | disclosed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023023269-A1 | IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-1691199-B1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO CO LTD (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20070249915-A1 | Inhibitors | SHISEIDO COMPANY, LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1691199-A1 | METHOD OF PREDICTING SPOT FORMATION ON THE SKIN WITH THE USE OF SPOT SITE-ACCELERATING GENES AS INDICATION AND METHOD OF SCREENING INHIBITOR FOR SPOT FORMATION ON THE SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | CCR3, CCR1, CCRL2 | RAB9A 2411/4885NPC1 1631/4885TP53 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.